Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene.
Gene therapy using the herpes simplex virus thymidine kinase gene (HSV-TK) is a promising new approach for the treatment of gliomas, a tumor type with a poor prognosis. To limit the toxic effects of this procedure, it is desirable to restrict expression of the HSV-TK gene to the target cells. This can be accomplished by use of the promoter of the glial fibrillary acidic protein gene, an intermediate filament protein expressed primarily in astrocytes. A plasmid containing the HSV-TK gene, driven by the human glial fibrillary acidic protein promoter gfa2, was lipofected into glioma cell lines and into an ovarian cancer cell line. Treatment with ganciclovir showed efficient killing of glioma cells, with no effect on the ovarian cells. Thus, the gfa2 promoter is a promising candidate for directing expression of toxic genes to gliomas.
Vandier
D
D
Département de Pharmacotoxicologie et Pharmacogénétique (UMR 1772 CNRS), Institut Gustave-Roussy, Villejuif, France.
Rixe
O
O
Brenner
M
M
Gouyette
A
A
Besnard
F
F
D001253:Astrocytes / Q000378:metabolism*; D015774:Ganciclovir / Q000494:pharmacology; D015316:Genetic Therapy; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis / Q000235:genetics; D005910:Glioma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D011401:Promoter Regions, Genetic; D018139:Simplexvirus / Q000201:enzymology*; D013937:Thymidine Kinase / Q000235:genetics*; D014407:Tumor Cells, Cultured
D005904:Glial Fibrillary Acidic Protein; D013937:Thymidine Kinase; D015774:Ganciclovir